Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2917051 | 0.86 | PTGS1 (0.56) | CYP4F2CYP4A11PTGS1PTGS2L3MBTL1 | |
| SCHEMBL17083283 | 0.85 | LOXL2 (0.45) | PTGS1PTGS2L3MBTL1MAPK1TSHR | |
| Hydrochloric Acid SCHEMBL17077498 | 0.84 | LOXL2 (0.44) | PTGS1PTGS2L3MBTL1MAPK1TSHR | |
| SCHEMBL11067869 | 0.84 | PTGS1 (0.47) | PTGS1PTGS2L3MBTL1MMP8LMNA | |
| SCHEMBL5216236 | 0.82 | APP (0.44) | CYP4F2CYP4A11PTGS1PTGS2ALDH1A1 | |
| SCHEMBL27697908 | 0.82 | PTGS1 (0.40) | CYP4F2CYP4A11PTGS1PTGS2MAPK1 | |
| SCHEMBL11189555 | 0.81 | ALDH1A1 (0.46) | PTGS1PTGS2MAPK1TSHRMMP8 | |
| SCHEMBL2391075 | 0.81 | PTGS2 (0.54) | PTGS1PTGS2MAPK1TSHRLMNA | |
| SCHEMBL3242802 | 0.81 | PTGS2 (0.54) | PTGS1PTGS2MAPK1TSHRLMNA | |
| SCHEMBL4210524 | 0.81 | PTGS1 (0.45) | PTGS1PTGS2L3MBTL1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106381092-A | Environment-friendly all-purpose adhesive | 无锡万能胶粘剂有限公司 | 2017-02-08 | — | — | CN | claimed |
| CN-108586233-A | The method for synthesizing 2- (4 ' -2-bromomethylphenyl) propionic ester | 湖北迅达药业股份有限公司 | 2018-09-28 | — | — | CN | disclosed |
| CN-105214692-B | Supported solid catalyst and preparation method thereof and its application | 湖北迅达药业股份有限公司 | 2017-09-29 | — | — | CN | disclosed |
| CN-106381092-A | Environment-friendly all-purpose adhesive | 无锡万能胶粘剂有限公司 | 2017-02-08 | — | — | CN | disclosed |
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-12 | — | — | US | disclosed |
| EP-1550662-B1 | ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-8148371-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-04-03 | — | — | US | disclosed |
| US-8148371-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-7754728-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
| US-7754728-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
| CN-101062892-A | Synthesis of 2-(4-Bromomethylphenyl) ethylformic acid | HANGZHOU PENTATOMIC SCIENCE & (CN) | 2007-10-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | ADORA1, P2RY10, HRH4 | CYP4F2 455/4885CYP4A11 24/4885PTGS1 1141/4885 |
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | ADORA1, HRH4, P2RY10 | CYP4F2 387/4885CYP4A11 15/4885PTGS1 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.